Septerna

SEPN · NASDAQ

$39.35+$2.97 (+8.16%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $36.38

Latest news

Press releaseAug 25, 8:00 AM ETGlobe Newswire
Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer
Press releaseAug 10, 4:01 PM ETGlobe Newswire
Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results
Press releaseJun 8, 8:00 AM ETBusiness Wire
Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting
Press releaseMay 11, 4:01 PM ETGlobe Newswire
Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results
NewsMar 9, 4:22 PM ET
Earnings Breakdown: Septerna Q4
NewsMar 9, 4:16 PM ET
Earnings Summary: Septerna Q4
Press releaseMar 9, 4:05 PM ETGlobe Newswire
Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
NewsMar 2, 1:00 PM ET
Septerna Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Press releaseMar 1, 9:45 AM ETGlobe Newswire
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy
NewsJan 20, 9:00 AM ET
The Analyst Verdict: Septerna In The Eyes Of 6 Experts
NewsDec 23, 9:47 AM ETAvi Kapoor
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
NewsNov 10, 7:45 AM ET
Septerna Q3 EPS $0.18, Inline, Sales $21.495M Miss $35.000M Estimate
Press releaseNov 10, 7:00 AM ETGlobe Newswire
Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results
Press releaseSep 29, 4:01 PM ETGlobe Newswire
Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors
Press releaseAug 11, 4:01 PM ETGlobe Newswire
Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results
NewsJun 23, 2:30 PM ETVandana Singh
Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside
NewsJun 23, 8:02 AM ET
The Analyst Verdict: Septerna In The Eyes Of 4 Experts
NewsMay 16, 2:00 PM ET
Where Septerna Stands With Analysts
NewsMay 16, 8:37 AM ETAkanksha Bakshi
Ozempic Maker Novo Nordisk Looks For New Chief, Jørgensen Steps Down From CEO Role
Press releaseMay 15, 4:01 PM ETGlobe Newswire
Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results
NewsMay 14, 1:06 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsMay 14, 12:15 PM ETAvi Kapoor
Dow Edges Higher; US Crude Oil Inventories Increase
NewsMay 14, 9:43 AM ETVandana Singh
Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs
NewsMay 14, 9:42 AM ETAvi Kapoor
Nasdaq Gains Over 100 Points; Sony Group Posts Upbeat Earnings
NewsMay 14, 8:09 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsMay 14, 7:15 AM ET
Market-Moving News for May 14th
Press releaseMar 27, 8:00 AM ETGlobe Newswire
Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results
Press releaseMar 18, 1:34 PM ETBusiness Wire
SEPN Investors Have Opportunity to Join Septerna, Inc. Fraud Investigation with the Schall Law Firm
Press releaseMar 17, 3:03 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Septerna, Inc. - SEPN
NewsMar 14, 5:08 AM ETAvi Kapoor
Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Press releaseMar 11, 12:19 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Septerna, Inc. - SEPN
Press releaseMar 3, 2:05 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Septerna, Inc. - SEPN
Press releaseFeb 21, 9:00 PM ETGlobe Newswire
SEPTERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Septerna, Inc. on Behalf of Septerna Stockholders and Encourages Investors to Contact the Firm
Press releaseFeb 19, 6:00 PM ETGlobe Newswire
Kirby McInerney LLP Announces Investigation Against Septerna, Inc. (SEPN) on Behalf of Investors
NewsFeb 18, 2:17 PM ETAvi Kapoor
Crude Oil Gains 1.5%; Fluor Shares Plunge Following Downbeat Earnings
NewsFeb 18, 9:45 AM ETAvi Kapoor
US Stocks Mixed; NY State Business Activity Rises In February
NewsJan 24, 5:03 AM ETAvi Kapoor
Why Twilio Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket
NewsJan 22, 4:58 AM ETAvi Kapoor
Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Press releaseNov 20, 7:00 AM ETGlobe Newswire
Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer

Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results

Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting

Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results

Earnings Breakdown: Septerna Q4

Earnings Summary: Septerna Q4

Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

Septerna Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy

The Analyst Verdict: Septerna In The Eyes Of 6 Experts

This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Septerna Q3 EPS $0.18, Inline, Sales $21.495M Miss $35.000M Estimate

Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results

Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors

Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results

Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside

The Analyst Verdict: Septerna In The Eyes Of 4 Experts

Where Septerna Stands With Analysts

Ozempic Maker Novo Nordisk Looks For New Chief, Jørgensen Steps Down From CEO Role

Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

12 Health Care Stocks Moving In Wednesday's Intraday Session

Dow Edges Higher; US Crude Oil Inventories Increase

Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs

Nasdaq Gains Over 100 Points; Sony Group Posts Upbeat Earnings

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Market-Moving News for May 14th

Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results

SEPN Investors Have Opportunity to Join Septerna, Inc. Fraud Investigation with the Schall Law Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Septerna, Inc. - SEPN

Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Septerna, Inc. - SEPN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Septerna, Inc. - SEPN

SEPTERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Septerna, Inc. on Behalf of Septerna Stockholders and Encourages Investors to Contact the Firm

Kirby McInerney LLP Announces Investigation Against Septerna, Inc. (SEPN) on Behalf of Investors

Crude Oil Gains 1.5%; Fluor Shares Plunge Following Downbeat Earnings

US Stocks Mixed; NY State Business Activity Rises In February

Why Twilio Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket

Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights